Most tumor data, including for the best-characterized PPAR-α agonists, are for exposure concentrations inducing well above 50% carcinogenic potency (TD50; the daily dose inducing tumors in half of the mice that would otherwise have remained tumor-free) with less-than-lifetime administration. Here, PPARA is linked to neoplasm.